Investment Q&A

Q: I'm underweight on Well. How good is the latest news. Is it time to add for a full position?

Thanks

Q: I currently own XHC.

I see that VHT has a lot lower MER. Does it make sense to make a switch?
I assume VHT is more North America while XHC is global?

Also have about 4% in ABBV in an Registered Account with a 52% return. (thank your;)
Would it make sense to cut this down to 2% and add LLY?

LLY has had quite a run the last couple of years and that can be scary. Does LLY have a good runway?

Thanks.

Q: ESSA Pharma is just one example of an exciting pharma in a topically interesting (prostate cancer, aging population…) area but with impenetrable valuation characteristics. Can you say whether this stock’s prospects are worth its price? Are there other early-stage pharmas you like?

Q: would like your view on rx, last i could find was may 2023.
thank you

Q: IDEAYA Biosciences, Inc. (IDYA). Please give me your opinion about this company for next three to five years. Thanks

Q: Would you be able to please comment on LMAT (NASDAQ)? I believe the balance sheet is good, and about 10% insider ownership.

Is valuation okay vs it's growth rate? Do you see any concerning competition in their business? Any other comments?

Q: I am looking for new healthcare stocks after selling Lantheus and InMode in the last 6 months. I currently own WELL. Quite a few have had a good run up lately so not sure if they are good buys at current valuations. What are recommendations? US or CAD, doesn’t matter. Should I buy an ETF instead?
Thank you in advance

Q: Hi 5i
Currently a share holder of WBA....
Regarding previous 5i comments about WBA, its debt and large dividend.......
Now that WBA has cut dividend by nearly 50%, where do you see it going from here?
Is it a good time to consider or still require wait and see? Attractive entry point at what price?
What has to happen next in this story?
Thx
jim

Q: With Rexall up for sale, who do you feel could be potential buyers. Do you see NBLY in the bidding with the takeover in play?

Q: Morning 5iTeam,

Would you please comment on UHN's earnings and how how the stock will perform going forward.
Thanks,
H

Q: What are your thoughts on the Biotech ETC here? I have heard the argument that biotech is very beaten down, and that lowering of interest rates tends to booster the sector quite a bit, especially once IPOs begin to happen again.

Q: Can I get you option on Lantheus after they released preliminary fiscal year 2023. Buy, hold, or sell? Thank you

Q: This company seems to be doing a lot of things right. The ceo Dan Matlow knows this space well, based on my conversations with him a few years ago. It's business is primarily in the UK but it is making some inroads in Ontario. How does one go about evaluating this business: what comparable companies and what ratios etc do you use? Thank you as I am not very good at determining values in the software industry.

Q: Hi,

I'm low on healthcare according to the analytics tool. I have held XHC for a few years now and it's showing just a small gain. Is there anything a bit more "growthy" or should I just add to XHC?

Thanks
Robert

Q: I would like your opinion on Apellis Pharmaceuticals. I read Citron's research piece (was published in November) on this company new product -Syfovre- issues and make a little bit of research myself. Obviously Citron is mostly promotting its own short positions but this one seems a reasonnable bet considering the content of the report (see attached link). No warning letter yet by the FDA but it is surely a real possibility.


Thank you!

Michel C

https://citronresearch.com/wp-content/uploads/2023/11/Citron-Reports-on-Apellis-Pharmaceuticals.pdf

Q: Can you provide your comments and outlook for this name

Q: after the recent reverse split and additional financing, how many total shares are now outstanding and what % owned by insiders if available. Thanks

Q: I have owned Theratechnologies since 2018 and watched this stock fall since I purchased it. The stock has been rising the last few weeks and was up 23% on Friday. I couldn't find any exciting press releases that would explain the increase. Do you know of any reason for the recent increase?

The 5 analysts listed on Qtrade have a price target of anywhere from $5.50-$12.04. How much faith can we put in the price targets of analysts?

I was quite excited that it was up to $3.03 but just noticed there was a 4 for 1 stock split in August 2023 so my 700 shares are now only 175 shares. So rather than being down 60% I am actually down 90%. Yikes, I better not tell my wife about this trade!

My holdings in TH are only worth $530 now. Should I sell this loser now or is it worth waiting until the annual report (November year end) comes out?

Q: seems like a bit of a long shot high volume some analysts have high expectations could you comment please?

Q: Your thoughts on why the rapid fall lately and whether you think there could be a recovery.
Regards Jerry Gazarek